Epalrestat is an aldose reductase inhibitor, widely used clinically to improve diabetic peripheral neuropathy and has brought benefits to many patients. Like a double-edged sword, all medications may produce various adverse reactions while exerting therapeutic effects.
What Are the Side Effects of Epalrestat?
Digestive System Reactions
Epalrestat may cause digestive symptoms such as abdominal pain (incidence: 0.1%-0.5%), nausea (0.1%-0.5%), vomiting (<0.1%), diarrhea (<0.1%), loss of appetite (<0.1%), abdominal distension (<0.1%), and constipation (<0.1%).
Some patients may also experience heartburn (incidence unknown), and these reactions are usually related to the drug’s irritation to the gastrointestinal tract.
Liver Function Abnormalities
This drug may cause elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transferase (γ-GTP) (0.1%-0.5%); a small number of patients may have elevated bilirubin (<0.1%).
Changes in these indicators suggest that the drug may have a certain impact on liver cells, requiring regular monitoring.
Skin Allergic Manifestations
Patients with sensitive constitutions may experience allergic reactions such as rash, pruritus, erythema, and blisters (incidence <0.1%).
These symptoms usually appear in the early stage of medication, and close observation of skin changes is necessary.
Effects on Other Systems
Kidney-related: May cause elevated blood urea nitrogen (BUN) and creatinine (<0.1%); occasional oliguria and frequent urination (incidence unknown).
Hematological system: A small number of patients may develop anemia and leukopenia (<0.1%).
Systemic symptoms: Include fatigue, dizziness, headache, stiffness, weakness, limb pain, chest discomfort, palpitations, edema, and a burning sensation (<0.1%); as well as numbness, alopecia, purpura, elevated creatine kinase (CK), and fever (incidence unknown).
Severe Side Effects of Epalrestat
Hematological Toxicity
Thrombocytopenia (incidence unknown) is one of the most severe hematological adverse reactions of this drug.
Platelets are key cells for maintaining normal coagulation function. A significant decrease in their count may lead to a bleeding tendency, manifested as skin ecchymosis, epistaxis, gingival bleeding, etc., and may be life-threatening in severe cases.
Risk of Liver Damage
Epalrestat may cause fulminant hepatitis (incidence unknown), hepatic dysfunction (<0.1%), jaundice (incidence unknown), and even liver failure (incidence unknown).
These severe liver damages progress rapidly, and early signs such as loss of appetite, fatigue, dark urine, and yellowing of the skin and sclera must be highly vigilant.
Precautions for Epalrestat
Medication Technique Guidance
Administration time: 50mg each time, three times a day. Oral administration before meals can improve bioavailability.
PTP packaging warning: The drug must be taken out of the aluminum foil packaging before use. Accidental ingestion of the packaging may cause serious complications such as esophageal perforation and mediastinitis.
Urine color change: The drug and its metabolites may cause urine to turn yellowish-brown or red, which is a normal phenomenon but may affect the qualitative test results of bilirubin and ketone bodies in urine.
Monitoring Plan Recommendations
Routine monitoring: Regularly check blood routine, liver function, and renal function during medication.
Key monitoring: Closely monitor platelet count and liver function indicators.
Symptom monitoring: Pay attention to observing the improvement of neurological symptoms and other uncomfortable reactions.
